Insulin-Like Growth Factor 1 and Prostate Cancer Risk: A Population-Based, Case-Control Study

Abstract

Elevated serum IGF-1 levels may be an important predictor of risk for prostate cancer. However, our results do not support an important role for serum IGFBP-3 as a predictor of risk for this disease.

Glycemic index in chronic disease: a review

“…The results were independent from baseline prostate-specific antigen levels and remained statistically significant after adjusting for potential confounders such as weight, height, BMI, lycopene, androgen receptors and plasma hormone levels. The design of the study allowed the inference that high levels of circulating IGF-1 were not a consequence of disease progression as suggested also by other investigators who found no association between IGFs and prostate cancer stage (Wolk et al, 1998). IGFBPs have also been considered in relation to prostate cancer, particularly IGFBP-3 in epidemiological studies Glycemic index in chronic disease LS Augustin et al (Chan et al, 1998;Wolk et al, 1998).…”

“…The design of the study allowed the inference that high levels of circulating IGF-1 were not a consequence of disease progression as suggested also by other investigators who found no association between IGFs and prostate cancer stage (Wolk et al, 1998). IGFBPs have also been considered in relation to prostate cancer, particularly IGFBP-3 in epidemiological studies Glycemic index in chronic disease LS Augustin et al (Chan et al, 1998;Wolk et al, 1998). Most investigators have reported an inverse association between IGFBP-3 and prostate cancer risk (Chan et al, 1998;Thrasher et al, 1996;Kanety et al, 1993), although others have found no association (Wolk et al, 1998).…”

“…Insulin-like growth factors, particularly the IGF-1 family, have mitogenic and antiapoptotic activity in normal as well as in transformed prostate epithelial cells (Cohen et al, 1991;Rajah et al, 1997) and stimulate prostate growth in rodents (Torring et al, 1997). Epidemiological studies have shown a positive correlation between IGF-1 levels and prostate cancer risk (Chan et al, 1998;Mantzoros et al, 1997;Wolk et al, 1998). A four-fold increased risk was observed in the highest quartile of IGF-1 levels compared to the lowest level in a nested case-control study of 152 paired subjects (Chan et al, 1998).…”

“…IGFBPs have also been considered in relation to prostate cancer, particularly IGFBP-3 in epidemiological studies Glycemic index in chronic disease LS Augustin et al (Chan et al, 1998;Wolk et al, 1998). Most investigators have reported an inverse association between IGFBP-3 and prostate cancer risk (Chan et al, 1998;Thrasher et al, 1996;Kanety et al, 1993), although others have found no association (Wolk et al, 1998). A possible role of IGFs in prostate carcinogenesis is also suggested by mechanistic studies on Suramin, a drug used in the treatment of advanced prostate cancer, which was shown to suppress IGF-levels (Miglietta et al, 1993;Sartor et al, 1994).…”

Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study

“…A number of epidemiologic studies have shown a direct association between circulating IGF-I levels and breast cancer risk, especially in young women (Peyrat et al, 1993;Bruning et al, 1995;Bohlke et al, 1998;Hankinson et al, 1998;Toniolo et al, 2000;Muti et al, 2002;Yu et al, 2002). Elevated circulating IGF-I also has been found to be a potential cancer risk factor for cancers of other organs, such as the prostate (Mantzoros et al, 1997;Chan et al, 1998;Wolk et al, 1998;Stattin et al, 2000) and the colorectum (Ma et al, 1999;Giovannucci et al, 2000;Kaaks et al, 2000;Palmqvist et al, 2002).…”